About
Technology
Issues
FAQ
Links
Official Page
Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.